NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
Stock Information for NRX Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.